Amphetamine Sulfate Tablet
NDC Package 13107-260-01

11-digit billing NDC: 13107026001

Package Information

Amphetamine Sulfate tablets is uSP are indicated for:NarcolepsyAttention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. This formulation utilizes a tablet delivery system. Marketed by Aurolife Pharma, Llc, this product is identified by NDC 13107-260 and is authorized under FDA application ANDA211639.

Identification & Billing

NDC Package Code
13107-260-01
Package Description
100 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
13107026001
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Amphetamine Sulfate
Non-Proprietary Name
Amphetamine Sulfate
Substance Name
Amphetamine Sulfate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Amphetamine Sulfate Tablets USP are indicated for:NarcolepsyAttention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted.Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patient’s refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY) should be weighed against possible risks inherent in use of the drug, such as those described below.
DEA Schedule
Schedule II (CII) Substances

Regulatory & Marketing

Labeler Name
Aurolife Pharma, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA211639
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-31-2019
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 13107-260-01 identifies a specific commercial package of 100 tablet in 1 bottle of Amphetamine Sulfate, a human prescription drug labeled by Aurolife Pharma, Llc. This tablet is formulated for oral use and contains amphetamine sulfate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurolife Pharma, Llc on January 31, 2019. The current certification is valid through December 31, 2027.

How is this Aurolife Pharma, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 13107026001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
13107-260-01
11-Digit CMS (5-4-2)
13107-0260-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.